CD44 and prostate carcinoma: Moreover, HA also serves as a tumor-targeting ligand that recognizes CD44 overexpression on various tumor cell membranes such as prostate cancer, breast cancer, and non–small cell lung cancer, and thus HA-coated NCs can also actively target to tumors after systemic administration.